The classic Chimeric Antigen Receptor Macrophage (CAR-M) exerts pro-inflammatory effects to achieve anti-tumor immunity, but by modifying the structure design of CAR, it can acquire anti-inflammatory functions similar to M2, thereby treating inflammatory diseases. Currently, CAR-M therapy targeting M1-type microglial cells can effectively reduce neuroinflammation and be used to treat inflammation-related depression. With ongoing research on the anti-inflammatory effects of CAR-M, CAR-M cell therapy offers a new approach for treating inflammatory-related diseases.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!